loading page

COVİD-19 AND HYPERAMYLASEMİA
  • +1
  • Ferhat Bacaksız,
  • Berat Ebik,
  • Nazım Ekin,
  • Jehat Kılıc
Ferhat Bacaksız
Diyarbakir Gazi Yasargil Training and Research Hospital

Corresponding Author:feratson85@hotmail.com

Author Profile
Berat Ebik
Diyarbakir Gazi Yasargil Training and Research Hospital
Author Profile
Nazım Ekin
Diyarbakir Gazi Yasargil Training and Research Hospital
Author Profile
Jehat Kılıc
Diyarbakir Gazi Yasargil Training and Research Hospital
Author Profile

Abstract

Object: Our aim is to evaluate the elevation of pancreatic enzymes in COVID-19 patients and their relationship with severity of COVID-19. Method: In this study, 1378 patients with COVID-19 infection were included. Relation of elevated amylase and lipase levels and co-morbid conditions with the severity of COVID-19 were checked. The effect of hemodynamic parameters and organ failures on pancreatic enzymes and their relations with prognosis were statistically analyzed. Results: There were 678 (%49,2) female patients and 700 (50,8%) male patients. Of all patients, 687 (49,9%) had mild, 691 (50,1%) severe COVID-19 infections. Elevated amylase levels were detected in 23% of patients (n:316). 19% (261) of them had a slight (1-3 times) increase in amylase levels, while 4% (55) had a more than 3 times increase in amylase than normal. Only 6% of patients with elevated amylase leves had the acute pancreatitis according to Atlanta criteria. According to univariate and multivariate analyses, elevated amylase levels was found statistically related with severity of COVID-19 (OR:4,37-p <0,001). And also diabetes mellitus (DM) (OR:1,82-p:0,001), kidney failure (OR:5,18- p< 0,001), liver damage (OR:6,63 p < 0,001), hypotension (OR:6,86-p< 0,001), sepsis (OR:6,20-p:0.008) were found to related to death of COVID-19. Conclusions: Elevated pancreatic enzyme levels in COVID-19 infections is to related to severity of COVID-19 infection and hemodynamic instability. Similar to other organs, the pancreas can be affected by severe COVID-19 infection.
03 Apr 2021Submitted to International Journal of Clinical Practice
07 Apr 2021Submission Checks Completed
07 Apr 2021Assigned to Editor
08 Apr 2021Reviewer(s) Assigned
10 May 2021Review(s) Completed, Editorial Evaluation Pending
22 Jun 20211st Revision Received
23 Jun 2021Submission Checks Completed
23 Jun 2021Assigned to Editor
23 Jun 2021Review(s) Completed, Editorial Evaluation Pending
23 Jun 2021Reviewer(s) Assigned
28 Jul 2021Editorial Decision: Accept